Tue Apr 29 10:30:00 UTC 2025: ## Pfizer Faces Q1 Challenges, but History Suggests Potential Upside
**New York, NY** – Pfizer (NYSE:PFE) reports its first-quarter earnings on Tuesday, and analysts predict a decline in both earnings per share (EPS) and revenue compared to the same period last year. Wall Street forecasts adjusted EPS of $0.69, down from $0.82, on revenue of $14.11 billion, a 5.3% decrease. However, Pfizer has a history of exceeding expectations, beating EPS forecasts in each of the last eight quarters and revenue estimates in five.
Despite concerns about patent expirations for key drugs like Ibrance and Eliquis, and upcoming drug-pricing reforms, GuruFocus estimates Pfizer’s fair value at $28.82, approximately 25% above Monday’s closing price. This suggests the stock may be undervalued. While the stock has underperformed its healthcare peers recently, a strong Q1 report, including positive guidance on its pipeline, could lead to a price increase. Investors will be closely watching management’s strategy for navigating these challenges and their outlook for future growth.
First Piper 